New research suggests GLP-1 drugs may have a role in reducing breast cancer risk, adding to the growing list of conditions these medications could potentially help address.
At the 2026 American Society of Clinical Oncology Annual Meeting, attendees highlighted oncology as a promising area for further investigation. Researchers from the University of Pennsylvania presented a retrospective study examining the association between GLP-1 use and breast cancer incidence. Using the data collected from more than 110,000 patients, they found that women taking GLP-1 medications were 30% less likely to develop breast cancer compared to women not on GLP-1s.
This study does not establish a causal role for GLP-1 receptor agonists in reducing breast cancer risk. The researchers said the findings simply provide a compelling rationale for further research. They plan to launch a multisite prospective trial to evaluate treatment effects in women with elevated breast cancer risk.
New Indications Will Expand Prescribing And Profitability
Byetta became the first FDA-approved GLP-1 receptor agonist in 2005. However, the class gained mainstream adoption ten years later, following the approval of Ozempic.
Ozempic’s pop culture prominence, coupled with off-label use, helped propel GLP-1 therapies into the mainstream. The expansion of telehealth during the COVID-19 pandemic, aided by temporary relaxation of telemedicine prescribing regulations, further accelerated adoption. Now, J.P. Morgan analysts estimate that 30 million Americans will be taking a GLP-1 therapy by 2030.
Market for GLP-1 therapies would expand beyond estimates should new indications gain regulatory approval. For drug manufacturers, expanded patent population could translate into higher revenue, increased profitability and valuations.
However, as indications expand patients eligibility, insurance may implement more utilization management strategies to control costs. For clinicians, these management requirements may translate into higher administrative burdens.
Still, broader coverage could create new treatment and reimbursement opportunities. At the same time, it would likely add administrative workload resulting from active payer access management strategies.
New Understanding Of Metabolic Health Is Reshaping Chronic Treatments
Metabolic dysfunction is increasingly recognized as a common pathway connecting multiple diseases. The evolved view on shared metabolic drivers has driven investigation into diseases historically treated in silo.
Obesity, insulin resistance, inflammation and excess adiposity share interconnected metabolic pathways that contribute to systemic disease and organ damage risk.
GLP-1s are a class of drugs that mimic the natural hormone glucagon-like peptide-1 to regulate glucose metabolism, appetite and energy balance.
Initially approved for diabetes, GLP-1 therapies now play a broader role in obesity treatment and cardiovascular risk management. Emerging evidence has prompted new investigational disease areas.
Investigational conditions for GLP-1s include cardiovascular diseases, kidney diseases, liver diseases, neurodegenerative diseases, substance use disorders, polycystic ovary syndrome, obstructive sleep apnea and knee osteoarthritis.
Studies Establish GLP-1 Heart Health Benefits
The American Heart Association recognizes GLP-1 receptor agonists as part of cardiovascular risk management for patients with type 2 diabetes. Studies suggest treatment improves cardiovascular health through indirect benefits from weight loss and direct biological effects on the cardiovascular system.
A systematic review published in the Journal of Endocrinology suggests the drugs may directly influence the cardiovascular system. The review notes that GLP-1 receptor is expressed in cardiovascular tissues, indication direct effect.
Still, researchers have not fully uncovered the underlying action driving cardiovascular benefits within the body. Some studies indicate GLP-1s reduce inflammatory markers in addition to promoting weight loss. These effects include lower inflammatory markers associated with plaque buildup, blood vessel dilation and reduced blood pressure.
FDA Expand Indications Beyond Weight And Diabetes Management
Regulators expanded GLP-1 receptor agonist indications to include cardiovascular risk reduction in select patients with type 2 diabetes and obesity.
Last year, the U.S. Food and Drug Administration approved oral GLP-1 receptor agonist Rybelsus to reduce the risk of major adverse cardiovascular events. Regulators also approved Wegovy for a cardiovascular indication, making it the first weight-loss medication approved to reduce cardiovascular event risk.
For clinicians managing cardiovascular risk, emerging evidence supports the role of GLP-1 therapies as long-term strategies rather than short-term interventions. Data suggest cardiovascular benefits build with continued therapy and gradually decline after treatment stops.
A 2026 study published in BMJ Medicine examined three years of continuous GLP-1 use among patients with type 2 diabetes. Sustained treatment was associated with an 18% lower incidence of major adverse cardiovascular events.
When patients discontinued GLP-1 treatment rates of major adverse cardiovascular events increased by 4% higher. The incidence progressively rose with longer treatment interruptions, increasing to 14% after one year and 22% after two years.
Clinical Trials Suggest Potential Benefit In Fatty Liver Disease
Evidence also suggests GLP-1 therapies may address several drivers of fatty liver disease. This has accelerated investment in next-generation dual GLP-1/glucagon receptor agonists, such as survodutide and pemvidutide.
These dual agonists are currently in late stage human clinical trial for obesity and metabolic liver disease. If approved by regulators, these medications could represent a shift toward multi-pathway metabolic therapies designed to address multiple disease drivers.
Early data suggest they may provide liver benefits beyond weight loss through potential direct cellular and anti-inflammatory effects. Clinical trials have reported promising signals.
Phase 3 data for survodutide showed that up to 84% of patients reduced liver fat by more than 30%. Visceral liver fat reduction was achieved in about 34% of patients and about 61% of trial patients had liver normalization.
Phase 2 data for pemvidutide showed reduction of biomarkers associated with liver fat accumulation and fibrosis risk. Patients on 1.8 mg dose for 48 weeks reported 23.7% reduction in triglycerides. They also had a 15.4% reduction in cholesterol.
However, tolerability remains a key area for further investigation. Both trials reported gastrointestinal side effects, including nausea, diarrhea and bloating, with some patients discontinuing treatment due to adverse events.
Novo Nordisk is pursuing an expanded liver indication for semaglutide in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis.
The Phase 3 ESSENCE trial enrolled 1,197 patients with biopsy-confirmed MASH and moderate-to-advanced fibrosis. A 2.4 mg weekly dose of semaglutide led to MASH resolution without worsening fibrosis in 62.9% of participants, compared with 34.3% on placebo. Resolution was defined as steatohepatitis activity without fibrosis worsening,
Researchers Are Designing GLP-1 Therapies For Neurology
Brain degeneration remains a complex area of research. This complexity has been reflected in the limited number of disease-modifying treatments available for neurodegenerative diseases.
Scientists have long suspected that GLP-1 receptor agonists may influence neurodegenerative conditions, such as Alzheimer’s and Parkinson’s diseases.
A preclinical study in The Journal of Clinical Investigation found neuroprotective effects of GLP-1 receptor agonists in mice. These models suggest potential in suppressing brain inflammation, improving mitochondrial function and enhancing clearance of toxic proteins. The researchers also highlighted lower rates of dementia, Parkinson’s disease and multiple sclerosis among long-term GLP-1 receptor agonist users.
Those findings have not consistently translated into clinical benefit. Existing GLP-1 therapies showed promising changes in neurological biomarkers but have not translate to meaningful clinical improvements in human trials.
Novo Nordisk terminated its EVOKE Phase 3 trials after neurological biomarkers did not translate to clinical improvement in Alzheimer’s. GLP-1 studies on Parkinson’s have shown a similar pattern of limited clinical benefit.
The Parkinson’s Foundation emphasizes that current GLP-1 receptor agonists are not established disease-modifying therapies for Parkinson’s disease. However, the group notes that researchers remain optimistic about the GLP-1 pathway as drug development continues.
Some researchers believe that a deeper understanding of the pathway and improved drug design could ultimately produce better clinical outcomes.
Next-Generation GLP-1 Therapies Target The Brain
The limitations of first-generation GLP-1 therapies have shifted attention toward “neurology-first” drug candidates. These medications are being engineered to improve brain penetration and more directly modulate central nervous system.
High scientific risk, long development timelines and costs have made neurology challenging for investment. However, several biotechnology companies are pursuing this strategy despite the risk.
Kariya Pharmaceuticals’ KP405 is a dual GLP-1/GIP receptor agonist designed to improve brain penetration. The candidate remains in preclinical development.
Neuronasal is developing nose-to-brain delivery approaches for GLP-1 drugs. The company believes this strategy could increase drug exposure in the brain, potentially strengthening effects on neuroinflammation and disease-related pathways.
Neuraly previously advanced a GLP-1 candidate into Phase 2 trials for Parkinson’s disease but did not achieve significant clinical results. The company has since shifted its focus toward a disease-modifying strategy based on c-Abl inhibition.
